A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs PRS 343 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Pieris Pharmaceuticals
- 02 Oct 2017 According to a Pieris Pharmaceuticals, Inc. media release, the first patient has been dosed in this trial.
- 02 Oct 2017 According to a Pieris Pharmaceuticals, Inc. media release, status changed from planning to recruiting.
- 09 Aug 2017 According to a Pieris Pharmaceuticals media release, the company expects to to dose first patient in this trial very soon.